Predictors of blood pressure response to intensified and fixed combination treatment of hypertension:: The ACCOMPLISH Study

被引:40
作者
Kjeldsen, Sverre E. [1 ,2 ]
Jamerson, Kenneth A. [1 ]
Bakris, George L. [3 ]
Pitt, Bertram [1 ]
Dahlof, Bjorn [4 ]
Velazquez, Eric J. [5 ]
Gupte, Jitendra [6 ]
Staikos, Linda [6 ]
Hua, Tsushung A. [6 ]
Shi, Victor [6 ]
Hester, Allen [6 ]
Tuomilehto, Jaakko [7 ]
Ostergren, Jan [8 ]
Ibsen, Hans [9 ]
Weber, Michael [10 ]
机构
[1] Univ Michigan Hlth Syst, Ann Arbor, MI USA
[2] Univ Oslo, Ullevaal Hosp, Dept Cardiol, N-0407 Oslo, Norway
[3] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
[4] Sahlgrens Univ Hosp, Gothenburg, Sweden
[5] Duke Univ, Sch Med, Durham, NC USA
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Helsinki Univ Hosp, Helsinki, Finland
[8] Karolinska Univ Hosp, Stockholm, Sweden
[9] Glostrup Univ Hosp, Copenhagen, Denmark
[10] SUNY Downstate Med Coll, Brooklyn, NY USA
关键词
clinical trial; combination therapy; hypertension; predictor variables;
D O I
10.1080/08037050801972857
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background. Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) is an outcome study investigating aggressive antihypertensive combination treatment. It has achieved a larger fraction of overall patients with blood pressure (BP) < 140/90 mmHg (73.3%) and diabetic patients < 130/80 mmHg (43.3%) at 12 months of follow-up than any other large outcomes trial. We have analyzed baseline predictors of BPs and BP control at 12 months. Methods. Blinded baseline and 12-month BP was available in 10 173 patients of whom 6132 had diabetes. Univariate and multivariate logistic regression models were used for BP control at 12 months; simple and multiple regression models were used for absolute BP value at 12 months. A stepwise procedure was used to select significant predictors in multivariate analyses. Results. Mean (SD) BP fell from 145.5/80.2 mmHg (18.2/10.7 mmHg) at randomization to 132.7/74.7 mmHg (16/9.6 mmHg) at 12 months. The main baseline predictors of achieving BP control were region (USA), Caucasian race and taking lipid-lowering drugs. The predictors of uncontrolled BP were higher baseline systolic BP values, more previous antihypertensive medications, proteinuria and previous thiazide use. Conclusion. Patients in the USA, Caucasians and patients taking lipid-lowering therapy were most likely to reach BP targets with combination therapy. Strong predictors of uncontrolled hypertension were more severe hypertension, an established need for more antihypertensive drugs and target organ damage.
引用
收藏
页码:7 / 17
页数:11
相关论文
共 29 条
[1]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[2]  
Black HR, 1999, AM J HYPERTENS, V12, p113S
[3]   Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [J].
Brown, MJ ;
Palmer, CR ;
Castaigne, A ;
de Leeuw, PW ;
Mancia, G ;
Rosenthal, T ;
Ruilope, LM .
LANCET, 2000, 356 (9227) :366-372
[4]   PREVALENCE OF HYPERTENSION IN THE US ADULT-POPULATION - RESULTS FROM THE 3RD NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY, 1988-1991 [J].
BURT, VL ;
WHELTON, P ;
ROCCELLA, EJ ;
BROWN, C ;
CUTLER, JA ;
HIGGINS, M ;
HORAN, MJ ;
LABARTHE, D .
HYPERTENSION, 1995, 25 (03) :305-313
[5]  
Campo Carlos, 2002, J Clin Hypertens (Greenwich), V4, P35, DOI 10.1111/j.1524-6175.2002.00487.x
[6]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[7]  
Cushman William C, 2002, J Clin Hypertens (Greenwich), V4, P393
[8]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[9]   Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].
Dahlöf, B ;
Sever, PS ;
Poulter, NR ;
Wedel, H ;
Beevers, DG ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2005, 366 (9489) :895-906
[10]   Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension:: the Nordic Diltiazem (NORDIL) study [J].
Hansson, L ;
Hedner, T ;
Lund-Johansen, P ;
Kjeldsen, SE ;
Lindholm, LH ;
Syvertsen, JO ;
Lanke, J ;
de Faire, U ;
Dahlöf, B ;
Karlberg, BE .
LANCET, 2000, 356 (9227) :359-365